Cormorant Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Cormorant Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$8.45M	–	51
2026 Q1	$8.45M	Sell	50,000 -25,000	-33%	-$4.32M	0.42%	38
2025 Q4	$13.7M	Sell	75,000 -25,000	-25%	-$3.49M	0.63%	29
2025 Q3	$12.1M	Hold	100,000	–	–	0.84%	28
2025 Q2	$10.4M	Sell	100,000 -150,000	-60%	-$15.9M	0.78%	28
2025 Q1	$29.2M	Sell	250,000 -75,000	-23%	-$8.54M	2.19%	15
2024 Q4	$27.5M	Sell	325,000 -75,000	-19%	-$6.9M	1.51%	21
2024 Q3	$35.9M	Hold	400,000	–	–	1.91%	20
2024 Q2	$32.2M	Buy	+400,000	New	+$29.6M	1.86%	15
2023 Q3	–	Sell	-340,000	Closed	-$24.4M	–	55
2023 Q2	$24.4M	Buy	340,000 +40,000	+13%	+$2.95M	1.37%	22
2023 Q1	$18.5M	Sell	300,000 -25,000	-8%	-$1.64M	1.22%	22
2022 Q4	$25.1M	Buy	+325,000	New	+$19.4M	1.68%	20
2022 Q3	–	Sell	-205,000	Closed	-$7.85M	–	76
2022 Q2	$7.85M	Buy	+205,000	New	+$6.48M	0.59%	44
2021 Q2	–	Sell	-200,000	Closed	-$11.3M	–	107
2021 Q1	$11.3M	Hold	200,000	–	–	0.25%	68
2020 Q4	$16.3M	Sell	200,000 -50,000	-20%	-$3.74M	0.39%	55
2020 Q3	$17.8M	Sell	250,000 -100,000	-29%	-$7.79M	0.68%	41
2020 Q2	$28.8M	Sell	350,000 -150,000	-30%	-$11.5M	1.1%	29
2020 Q1	$29.4M	Sell	500,000 -100,000	-17%	-$8.15M	1.37%	23
2019 Q4	$62M	Buy	+600,000	New	+$24.2M	2.47%	10

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cormorant Asset Management's AXSM Position: Q2 2026 in Review

Cormorant Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 50,000 shares — an estimated $8.45M sold.

Cormorant Asset Management first reported a position in AXSM in Q4 2019 and held it in 18 quarters. The position peaked at $62M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Cormorant Asset Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Cormorant Asset Management sold 50,000 Axsome Therapeutics shares in Q2 2026, an estimated $8.45M.
Cormorant Asset Management first reported a position in Axsome Therapeutics in Q4 2019 and held it in 18 quarters.
Cormorant Asset Management's Axsome Therapeutics position peaked at $62M in Q4 2019.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.